|
|
|
| Outsourced Pharma Capabilities Update August 2026: Cell Line Development (August 5th, 11:00am ET) | Cell line development is becoming a critical, high risk step in biologics programs, as early decisions must now scale without rework. Mistakes can lead to unstable expression, low yields, and tech transfer delays. In this August 5th session, CDMO experts will explore key choices in host cells, vector design, and clone screening — and how they affect scalability and manufacturability. Ideal for teams advancing biologics, it offers practical guidance to reduce downstream risk and improve program success. Register. |
|
|
|
|
|
| Precision Polymorph Screening With Electron Diffraction | Application Note | Ardena | See how polymorph screening with electron diffraction uncovers hidden forms, enabling precise identification and reliable quantification of minor phases affecting performance and manufacturability. |
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma | Asset development and outsourcing strategies can be intriguing, and full of global connections. Those attributes surface immediately in a conversation with Hyung Heon Kim, Chief Executive Officer and President, MetaVia, a Cambridge, Mass.-based biotech. The company reformed recently, but has roots back to 90 years of South Korean pharma history. Tracing the CDMO relationship MetaVia has is also part of the organization’s history. “Ours is a fun journey to tell,” says Kim. Fun, informative, and enlightening. | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
| Scaling Up Bioprocesses Through A CDMO | Q&A | Cytiva | Scaling biopharma processes is complex. Learn how flexibility, single-use systems, and strategic partnerships are helping manufacturers overcome these challenges and accelerate time to market. |
|
|
|
| Modular VFlexible Aseptic Filling Lines | Webinar | Kindeva | Modular suites with built-in contamination control streamline sterile manufacturing—supporting complex products, faster timelines, greater flexibility, less disruption, and scalable fill‑finish. |
|
|
| Five Tips For A Successful Tech Transfer To A CDMO | Article | 53Biologics | Successful tech transfer depends on solid documentation, early teamwork, clear expectations, proactive risk planning, and experienced partners to keep execution smooth and projects moving on schedule. |
|
|
| A Smooth Transition To USP <382> With Established Expertise | Q&A | BD Medical - Pharmaceutical Systems | A new regulatory chapter requires holistic, real‑world testing of injectable systems, mandating full‑system validation with actual drug products and prioritizing patient‑centric performance and safety. |
|
|
| Streamlining Biologics Process Validation | Webinar | Thermo Fisher Scientific | Uncover how data-driven process design, effective technology transfer, and robust process characterization can accelerate validation readiness. |
|
|
|
| What DEL-Derived Hits Reveal About Library Design | Infographic | X-Chem | Balanced chemical properties drive more efficient optimization and reduce risk. Discover how chemistry-driven library design consistently produces more tractable compounds, improving SAR productivity. |
|
|
| SPTFF High Concentration mAb Formulation Case Study | Case Study | By Chris Marlein, Matthew Dillingham, Evie Wood, et al., FUJIFILM Biotechnologies | Assimilate how single-pass tangential flow approaches improve efficiency, scalability, and product quality while addressing key development and processing challenges. |
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
